Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01540929 · ClinicalTrials.gov registry record
Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
A clinical trial of Smallpox, sponsored by Emergent BioSolutions.
- Completed
- Registry status
- 5,001
- Enrollment target
- 1
- Study location
NCT01540929 is a study of Smallpox that has completed, run by Emergent BioSolutions. The registered enrollment target is 5,001 participants, below the 130,337-participant average among 7 other Smallpox trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01540929, a study of Smallpox, has completed, sponsored by Emergent BioSolutions.
- COMPLETED
- Registry status
- 5,001 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a retrospective study of the Department of Defense (DoD) Smallpox Screening Form 600s (SF600s) generated during screening of service members for possible immunization with the ACAM2000® smallpox vaccine. Primary Objective: * To evaluate the accuracy of the DoD smallpox vaccination screening process in military personnel. Secondary Objective: * To describe the number of subjects who are excluded from vaccination, stratified by the pre-defined categories for exclusion (separately for the Screened and Evaluable Populations).
Conditions Studied
Study Locations (1)
Virginia
- - Alexandria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,001 participants |
| Start Date | 2009-09 |
| Est. Completion | 2012-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01540929
The ClinicalTrials.gov registry entry for NCT01540929 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5,001 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 130,337-participant average among 7 other Smallpox trials with a reported enrollment target (96% lower). The listed sponsor is Emergent BioSolutions, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smallpox appearing as the primary indexed condition, and to 0 interventions.
NCT01540929 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT01540929 about?
NCT01540929 is a clinical study titled "Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel". This is a retrospective study of the Department of Defense (DoD) Smallpox Screening Form 600s (SF600s) generated during screening of service members for possible immunization with the ACAM2000® smallpox vaccine. Primary Objective: * To evaluate the accuracy of the DoD smallpox vaccination screenin...
What is the current status of trial NCT01540929?
This trial is currently completed. The enrollment target is 5,001 participants. The study started on 2009-09. Estimated completion is 2012-09.
What conditions does trial NCT01540929 study?
This clinical trial studies the following conditions: Smallpox.
Who is sponsoring clinical trial NCT01540929?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01540929 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smallpox
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
ACTIVE NOT RECRUITING · Phase 2
-
Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
COMPLETED
-
Safety Surveillance Study of ACAM2000® Vaccinia Vaccine
COMPLETED
-
MVA Post-Event: Administration Timing and Boost Study
COMPLETED · Phase 1
-
Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally
COMPLETED · Phase 2
-
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.